Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very strong margins and returns
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Bob Prince, Greg Jensen, Karen Karniol-Tambour | Bridgewater Associates | 0.0% | +0.01% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | -0.00% |
About
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA,
Target Price
The average target price of HRMY is 44.4 and suggests 10.2% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio